Wu H, Sun HC, Ouyang GF. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma. World J Clin Cases 2022; 10(32): 11804-11811 [PMID: 36405294 DOI: 10.12998/wjcc.v10.i32.11804]
Corresponding Author of This Article
Gui-Fang Ouyang, MD, Chief Physician, Department of Hematology, Ningbo First Hospital, Ningbo Clinical Research Center for Hematologic Malignancies, No. 59 Liuting Street, Ningbo 315010, Zhejiang Province, China. oyguifangoy@163.com
Research Domain of This Article
Hematology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2022; 10(32): 11804-11811 Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11804
T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma
Hao Wu, Hui-Cong Sun, Gui-Fang Ouyang
Hao Wu, Gui-Fang Ouyang, Department of Hematology, Ningbo First Hospital, Ningbo Clinical Research Center for Hematologic Malignancies, Ningbo 315010, Zhejiang Province, China
Hui-Cong Sun, Department of Adult Internal Medicine, Ningbo Women and Children's Hospital, Ningbo 315012, Zhejiang Province, China`
Author contributions: Wu H and Ouyang GF for their help in research ideas and design; Ouyang GF for supervision and writing the review; Wu H and Sun HC for their role in research implementation, data collection, and manuscript submission; Wu H for statistical analysis, manuscript editing, and writing.
Supported byNingbo Science and Technology Program, No. 2019A6-10312.
Institutional review board statement: This study was reviewed and approved by Ningbo First Hospital.
Informed consent statement: All study participants or their legal guardians provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare no conflicts of interest related to this study.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE statement checklist of items, and the manuscript was prepared and revised according to the STROBE statement checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gui-Fang Ouyang, MD, Chief Physician, Department of Hematology, Ningbo First Hospital, Ningbo Clinical Research Center for Hematologic Malignancies, No. 59 Liuting Street, Ningbo 315010, Zhejiang Province, China. oyguifangoy@163.com
Received: August 1, 2022 Peer-review started: August 1, 2022 First decision: August 21, 2022 Revised: September 8, 2022 Accepted: October 19, 2022 Article in press: October 19, 2022 Published online: November 16, 2022 Processing time: 98 Days and 21.9 Hours
ARTICLE HIGHLIGHTS
Research background
Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with biological heterogeneity characterized by high recurrence, high malignancy, and poor overall prognosis. Exploring the prognostic factors and therapeutic targets of DLBCL is crucial to improve patient prognosis. T-cell immunoglobulin and mucin domain 3 (Tim-3), transforming growth factor β (TGF-β), and chemokine 12 (CXCL12) are closely related to immune function and can affect the prognosis of various solid tumors by participating in tumor immune escape.
Research motivation
Owing to limited reports on the role of Tim-3, TGF-β, and CXCL12 expression in the prognosis of DLBCL, their effects on the prognosis of DLBCL patients remain unclear.
Research objectives
We investigated the relationship between Tim-3, TGF-β, and CXCL12 expression and DLBCL prognosis.
Research methods
The lymph node tissues of 97 patients with DLBCL and 93 patients with normal reactive hyperplasia were selected as DLBCL and control groups, respectively. The expression of Tim-3, TGF-β, and CXCL12 was detected using immunohistochemistry. The patients were followed up for 3 years, and progression-free survival was recorded. Cox multivariate analysis was used to analyze the risk factors for poor prognosis.
Research results
Clinical stage III–IV, bone marrow infiltration, high-risk IPI score, Tim-3 positivity, TGF-β positivity, and CXCL12 positivity were independent risk factors affecting the prognosis of DLBCL.
Research conclusions
Tim-3, TGF-β, and CXCL12 have high positive expression rates in DLBCL and can be used to evaluate the efficacy and prognosis of R-CHOP chemotherapy. In addition, these factors may serve as potential prognostic biomarkers for DLBCL.
Research perspectives
Future work and clinical research can further validate the accuracy of the experimental results by expanding the sample size and conducting multicenter studies, and ultimately applying the results to the prognostic analysis of DLBCL.
